| 34.09 -0.29 (-0.84%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.67 | 1-year : | 41.37 |
| Resists | First : | 34.82 | Second : | 35.41 |
| Pivot price | 34.6 |
|||
| Supports | First : | 33.86 | Second : | 28.17 |
| MAs | MA(5) : | 34.2 |
MA(20) : | 34.67 |
| MA(100) : | 34.48  |
MA(250) : | 26.62 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 21.7 |
D(3) : | 19.1 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 39.79 | Low : | 14.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INBX ] has closed above bottom band by 11.1%. Bollinger Bands are 76.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 34.26 - 34.45 | 34.45 - 34.63 |
| Low: | 33.56 - 33.78 | 33.78 - 33.97 |
| Close: | 33.78 - 34.13 | 34.13 - 34.44 |
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Fri, 12 Apr 2024
Inhibrx Becomes Oversold (INBX) - Nasdaq
Mon, 08 Apr 2024
Inhibrx (NASDAQ:INBX) Sees Large Volume Increase - MarketBeat
Thu, 21 Mar 2024
Do Analysts Agree Thursday on Inhibrx Inc (INBX) Stock's Target Price? - InvestorsObserver
Wed, 28 Feb 2024
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results - PR Newswire
Tue, 23 Jan 2024
Sanofi to acquire Inhibrx rare disease asset in $2.2B deal (NASDAQ:SNY) - Seeking Alpha
Tue, 23 Jan 2024
Sanofi set to acquire Inhibrx assets for up to $2.2 billion - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 2.198e+007 (%) |
| Held by Institutions | 19.5 (%) |
| Shares Short | 1,950 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1803e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 403.2 % |
| Return on Equity (ttm) | -45.8 % |
| Qtrly Rev. Growth | 1.8e+006 % |
| Gross Profit (p.s.) | 170.58 |
| Sales Per Share | -163.34 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -193 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.21 |
| Price to Cash Flow | 107.82 |
| Dividend | 0 |
| Forward Dividend | 2.15e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|